Glucose starvation mimetic aldometanib removes immune barriers permitting mice with hepatocellular carcinoma to live to normal ages
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-25 15:32
摘要：
Aldometanib, a glucose starvation mimetic, shows promise in treating hepatocellular carcinoma (HCC) by activating AMPK and enhancing the immune response. In mouse models, it significantly inhibits tumor growth and allows mice to live to normal ages, indicating a potential breakthrough in cancer therapy. The study highlights the metabolic intervention strategy as a novel approach to managing cancer, suggesting that metabolic regulation can transform cancer into a manageable disease.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
Aldometanib allows HCC-bearing mice to live to normal ages.
The drug activates AMPK and enhances CD8+ T cell infiltration.
Aldometanib does not exert cytotoxicity towards normal cells.
真实性检查
否
AI评分总结
Aldometanib, a glucose starvation mimetic, shows promise in treating hepatocellular carcinoma (HCC) by activating AMPK and enhancing the immune response. In mouse models, it significantly inhibits tumor growth and allows mice to live to normal ages, indicating a potential breakthrough in cancer therapy. The study highlights the metabolic intervention strategy as a novel approach to managing cancer, suggesting that metabolic regulation can transform cancer into a manageable disease.